The BioMedical Value Fund (“BMVF”) invests in small and mid-capitalization, publicly traded biotechnology and life sciences companies that are transforming medicine.
The BMVF team employs a deep value, fundamentals focused investment approach, leveraging a proprietary research team with deep financial and scientific expertise and seeks to identify asymmetric risk reward dynamics within the universe of publicly traded life sciences companies.
Spark Therapeutics (ONCE), a leader in gene therapy, having secured the first gene therapy FDA product approval in 2017, announced it would be acquired by Roche.
February 2019
In September 2017 we led a new investment in Iovance Biotherapeutics (IOVA), the leading cell therapy company developing autologous cellular immunotherapies optimizing personalized, tumor directed Tumor Infiltrating Lymphocytes (TIL). In May 2019 IOVA released exciting new data in solid tumor patients, reducing concerns that the product would not be durable.
May 2019
Amarin Corp (AMRN) announced positive results from a global study comparing its drug, Vascepa to placebo. Vascepa demonstrated a 25% risk reduction in major adverse cardiovascular events.
September 2018
Our Key Differentiators
Life Sciences Focus
BMVF exclusively invests in the biotechnology sector. Since our founding in 2003, we have invested in and worked with over 200 life sciences companies, providing capital to continue research and development, execute on clinical trials and to launch new products.
Experienced Investors
The senior team has a combined 50+ years of experience investing in the life sciences universe and brings the full breadth of that experience to discussions with management teams. Our team has deep training in medical, scientific and financial disciplines.
High Conviction Investing
We focus on companies that are making a difference for patients by developing life changing treatments. We invest for the long term and have the capability to support a company through its entire life cycle.
Partnership Focus
Since 2003, BMVF has served as a financial partner to management teams of public companies as they navigate the regulatory and commercial hurdles on the path to global regulatory approvals. We generate investment returns by being thoughtful and patient investors.
Directly Negotiated Investments (“DNIs”)
There are times when the capital markets are not functioning properly or a company has a complicated investment thesis. In situations like this, Great Point Partners is capable of providing 100% of the capital a company needs in a $25 to $75 million equity financing. We have a flexible mandate that allows for a customized solution to meet each company’s specific needs.